Synonyms: Olinvyk® | TRV130 | TRV130A
oliceridine is an approved drug (FDA (2020))
Compound class:
Synthetic organic
Comment: Oliceridine (TRV130) is an opioid compound. It was developed to exhibit biased-signalling (specifically bias towards G protein signalling), with the aim of reducing the adverse effects associated with use of other opioid drugs [1-2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Oliceridine (TRV130) is administered intravenously. It was evaluated in human clinical trial for the treatment of acute severe pain [3]. Click here to view the full list of oliceridine trials registered at ClinicalTrials.gov. Oliceridine received FDA approval in August 2020, for the management of acute pain that requires intravenous opioid analgesia and that is not adequately responsive to alternative treatments. |
Mechanism Of Action and Pharmacodynamic Effects |
Oliceridine is an agonist of the opioid μ receptor (OPRM1) [1]. |
Pharmacokinetics |
Absorption/Distribution |
Initial pharmacokinetic and pharmacodynamic data from clinical use of this compound is reported by Soergel et al (2014) [3]. |